Dendreon's New Double-Twist

by Jon C. Ogg
24/7 Wall St.



Dendreon (DNDN) has an interesting twist this morning because of two issues. Yesterday it announced some new study data on PROVENGE at The American Urological Association on Sunday. The company's board has also approved a lay off of 40 workers to save cash burn rates, so it has two new datapoints today.

The abstract, "Advanced Prostate Cancer Patients who Receive Sipuleucel-T followed by Docetaxel Have Prolonged Survival," was authored by Daniel P. Petrylak, M.D., associate professor of medicine at New York- Presbyterian Hospital at the Columbia University Medical Center. It is based on an exploratory analysis conducted to assess the influence of the active cellular immunotherapy PROVENGE on the clinical outcome of patients who subsequently went on to receive docetaxel chemotherapy after primary treatment with PROVENGE. The analysis was conducted by evaluating data from two Phase 3 clinical trials of PROVENGE in patient with asymptomatic, metastatic, androgen-independent prostate cancer (AIPC).


Continue article at 247WallSt.com




RELATED READING:
- Dendreon, the Day That Could Have Been and What to Expect Now
- Rantasorous Rx
- Comments From Dendreon's Conference Call (May 10, 2007)
- Dendreon Gets Complete Response Letter
- Dendreon Nailed by FDA

___________________